Sign In
Buy LLY
$1,185.71
-7.09 (-0.594%)
At Close: Aug 07, 2026
Eli Lilly Reports Earnings Thursday Amid a Stock Slump
04:30pm, Wednesday, 07'th Aug 2024
Investors will be looking for updates on Zepbound's rollout, and projections for when supply shortages in the U.S. might end.
Eli Lilly: Bearish Signals Loom Over Weight Loss Stock Ahead Of Q2 Earnings
03:28pm, Wednesday, 07'th Aug 2024
Eli Lilly and Co LLY will be reporting its second-quarter earnings on Thursday. Wall Street expects $2.70 in EPS and $9.9 billion in revenues as the company reports before market hours.
NEW YORK, NY / ACCESSWIRE / August 7, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. ("Morphic") (NASDAQ:MORF) and Eli Lilly and Company ("Eli Lill
How To Earn $500 A Month From Eli Lilly Stock Ahead Of Q2 Earnings
09:26am, Wednesday, 07'th Aug 2024
Eli Lilly and Company LLY is expected to release earnings results for its second quarter, before the opening bell on Thursday, Aug. 8.
Eli Lilly (LLY) & Novo Nordisk (NVO) Earnings: A Closer Look
07:31pm, Tuesday, 06'th Aug 2024
Given their underperformance in 2024, a positive set of quarterly results could easily push both stocks higher.
Can Mounjaro & Zepbound Drive Eli Lilly (LLY) Q2 Earnings?
11:10am, Tuesday, 06'th Aug 2024
Investor focus is likely to be on the sales numbers of Lilly's (LLY) tirzepatide medicines Mounjaro and Zepbound.
Will The Supply Shortage Weigh On Eli Lilly's Q2?
10:00am, Tuesday, 06'th Aug 2024
Eli Lilly stock (NYSE: LLY) will report its Q2 results on Thursday, August 8. The pharmaceutical giant is expected to garner $10 billion in sales and $2.70 in adjusted earnings per share, per the cons
NEW YORK, NY / ACCESSWIRE / August 6, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. ("Morphic") (NASDAQ:MORF) and Eli Lilly and Company ("Eli Lill
Prediction: This Will Be the Best Pharmaceutical Stock to Own Over the Next 10 Years
09:53am, Tuesday, 06'th Aug 2024
Eli Lilly is a leader in diabetes and obesity care through its medications Mounjaro and Zepbound. Now, it's also set to enter the $31 billion Alzheimer's market following FDA approval of donanemab.
Prediction: These Could Be the Best-Performing Value Stocks Through 2030
05:34am, Tuesday, 06'th Aug 2024
These value-oriented businesses are also faithful dividend payers. Eli Lilly has scored multiple wins in recent months, and this established pharmaceutical giant is looking increasingly attractive for
The Final Peak Week Of The Q2 Season Begins Amid Souring Economic Data
03:20am, Tuesday, 06'th Aug 2024
This marks the last peak week of the Q2 earnings season with 3,908 companies expected to report. Earnings have come in better-than-expected, but tend to be overshadowed by economic data. Outlier earni
Will These 5 Medical Stocks Surpass Q2 Earnings Forecasts?
12:41pm, Monday, 05'th Aug 2024
Let's look at five biotech and drug companies, AMGN, GILD, LLY, VTRS & NVO, due to release their second-quarter 2024 results this week.
Should You Buy, Sell or Hold Lilly (LLY) Ahead of Q2 Earnings?
10:41am, Monday, 05'th Aug 2024
Investor focus is likely to be on the sales numbers of Lilly's (LLY) tirzepatide medicines Mounjaro and Zepbound.
Lilly (LLY) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
10:21am, Monday, 05'th Aug 2024
Besides Wall Street's top -and-bottom-line estimates for Lilly (LLY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quart
NEW YORK, NY / ACCESSWIRE / August 5, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. ("Morphic") (NASDAQ:MORF) and Eli Lilly and Company ("Eli Lill
